Equities research analysts expect that Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) will announce earnings per share of ($0.13) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharma’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.15). Arbutus Biopharma reported earnings per share of ($0.23) during the same quarter last year, which indicates a positive year-over-year growth rate of 43.5%. The firm is expected to report its next earnings report on Monday, January 1st.
On average, analysts expect that Arbutus Biopharma will report full year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.39). For the next financial year, analysts forecast that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.80) to ($0.40). Zacks’ EPS averages are an average based on a survey of analysts that cover Arbutus Biopharma.
Arbutus Biopharma (NASDAQ:ABUS – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Arbutus Biopharma had a negative net margin of 352.49% and a negative return on equity of 121.30%. The company had revenue of $12.58 million during the quarter, compared to analysts’ expectations of $5.77 million. During the same period in the prior year, the company posted ($0.21) earnings per share.
Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its stake in shares of Arbutus Biopharma by 15.9% in the third quarter. Invesco Ltd. now owns 29,180 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 3,994 shares in the last quarter. ETF Managers Group LLC lifted its stake in shares of Arbutus Biopharma by 13.1% in the fourth quarter. ETF Managers Group LLC now owns 40,934 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 4,727 shares in the last quarter. Citigroup Inc. lifted its stake in shares of Arbutus Biopharma by 53.5% in the third quarter. Citigroup Inc. now owns 14,679 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 5,117 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Arbutus Biopharma by 16.3% in the fourth quarter. ProShare Advisors LLC now owns 36,599 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 5,122 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Arbutus Biopharma by 13.6% in the fourth quarter. JPMorgan Chase & Co. now owns 42,737 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 5,126 shares in the last quarter. 26.66% of the stock is currently owned by hedge funds and other institutional investors.
ABUS opened at $2.40 on Friday. Arbutus Biopharma has a twelve month low of $1.93 and a twelve month high of $6.50. The company has a fifty day moving average of $2.66 and a 200-day moving average of $3.13. The stock has a market cap of $356.95 million, a PE ratio of -3.29 and a beta of 2.66.
Arbutus Biopharma Company Profile (Get Rating)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Time to Bid Low for Farfetch Stock
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Don’t Wait Too Long to Buy These 3 Mega Caps
- Cheap Buys: These 3 Stocks are Now Trading Under $20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.